Abstract
This study aimed to investigate the safety and feasibility of intracoronary injection of human umbilical cord mesenchymal stem cell to the very old patients with coronary chronic total occlusion. 15 consecutive patients received mesenchymal stem cells from human umbilical cord in epicardial coronary artery supplying collateral circulation. The patients were randomly allocated to low-dose 3x106, mid-dose 4x106 and high-dose 5x106 groups. 99mTc single photon emission computed tomography images were obtained at 12 and 24 months. During the 24 month study period, no cases of major cardiac adverse events were reported. None of the patients had coronary care unit admissionshospitalizationsfurther coronary revascularizationacute myocardial infarction and death. The patients had a significant reduction of the infarct size and a remarkable rise in left ventricular ejection fraction with respect to secondary outcomes. This study suggested that stem cell transplantation was safe and feasible. The cells can be utilized to improve in the degree of ischemic myocardium, decrease in the infarct size and rise in left ventricular ejection fraction.
Keywords: Chronic myocardial ischemia, elderly, human umbilical cord-derived mesenchymal stem cells, therapy.
Current Pharmaceutical Design
Title:Safety and Efficacy of Intracoronary Human Umbilical Cord-Derived Mesenchymal Stem Cell Treatment for Very Old Patients with Coronary Chronic Total Occlusion
Volume: 21 Issue: 11
Author(s): Xia Li, You-dong Hu, Yan Guo, Ying Chen, Dian-xuan Guo, Hua-lan Zhou, Feng-lin Zhang and Qing-na Zhao
Affiliation:
Keywords: Chronic myocardial ischemia, elderly, human umbilical cord-derived mesenchymal stem cells, therapy.
Abstract: This study aimed to investigate the safety and feasibility of intracoronary injection of human umbilical cord mesenchymal stem cell to the very old patients with coronary chronic total occlusion. 15 consecutive patients received mesenchymal stem cells from human umbilical cord in epicardial coronary artery supplying collateral circulation. The patients were randomly allocated to low-dose 3x106, mid-dose 4x106 and high-dose 5x106 groups. 99mTc single photon emission computed tomography images were obtained at 12 and 24 months. During the 24 month study period, no cases of major cardiac adverse events were reported. None of the patients had coronary care unit admissionshospitalizationsfurther coronary revascularizationacute myocardial infarction and death. The patients had a significant reduction of the infarct size and a remarkable rise in left ventricular ejection fraction with respect to secondary outcomes. This study suggested that stem cell transplantation was safe and feasible. The cells can be utilized to improve in the degree of ischemic myocardium, decrease in the infarct size and rise in left ventricular ejection fraction.
Export Options
About this article
Cite this article as:
Li Xia, Hu You-dong, Guo Yan, Chen Ying, Guo Dian-xuan, Zhou Hua-lan, Zhang Feng-lin and Zhao Qing-na, Safety and Efficacy of Intracoronary Human Umbilical Cord-Derived Mesenchymal Stem Cell Treatment for Very Old Patients with Coronary Chronic Total Occlusion, Current Pharmaceutical Design 2015; 21 (11) . https://dx.doi.org/10.2174/1381612821666141126100636
DOI https://dx.doi.org/10.2174/1381612821666141126100636 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Osteoprotegerin and Diabetes-Associated Pathologies
Current Molecular Medicine Perioperative Management of Patients on Adenosine Diphosphate Inhibitors in the Era of Drug-Eluting Stents: Review of the Literature and Clinical Implications
Current Medicinal Chemistry Molecular, Cellular and Clinical Aspects of Intracerebral Hemorrhage: Are the Enemies Within?
Current Neuropharmacology Cyclophilins in Atherosclerosis: A New Therapeutic Target?
Current Pharmaceutical Design Sonic Hedgehog Signaling Activation Promotes Cardioprotective Strategies
Current Signal Transduction Therapy Inflammatory Biomarkers and Therapeutic Targets in Heart Failure
Current Medicinal Chemistry Regulation of the Cardiac Sodium/Bicarbonate Cotransporter by Angiotensin II: Potential Contribution to Structural, Ionic and Electrophysiological Myocardial Remodelling
Current Cardiology Reviews Antivitamin K Drugs in Stroke Prevention
Current Vascular Pharmacology Advanced Glycation and ROS: A Link between Diabetes and Heart Failure
Current Vascular Pharmacology Chinese Herbal Medicine for Hyperlipidaemia: A Review Based on Data Mining from 1990 to 2016
Current Vascular Pharmacology Protein Phosphatase Inhibition: Structure Based Design. Towards New Therapeutic Agents
Current Pharmaceutical Design Obesity, Diabetes and Atrial Fibrillation; Epidemiology, Mechanisms and Interventions
Current Cardiology Reviews Role of Mechanical Stress in Monocytes / Macrophages: Implications for Atherosclerosis
Current Vascular Pharmacology Cardiac Regeneration: Stem Cells and Beyond
Current Medicinal Chemistry Circulating Endothelial Progenitor Cells Characterization, Function and Relationship with Cardiovascular Risk Factors
Current Pharmaceutical Design Patent Selections:
Recent Patents on Biomarkers Elevated Serum Human Cytomegalovirus IgM Levels in the Acute Phase of Ischemic Stroke are Associated with Increased Risk of Death and Major Disability
Current Neurovascular Research Antiarrhythmic Therapy on Prevention of Postoperative Atrial Fibrillation in Patients After Heart Surgery
Current Medicinal Chemistry - Cardiovascular & Hematological Agents Heart Failure Pharmacotherapy and Supports in the Elderly - A Short Review
Current Cardiology Reviews Endothelial Endocytic Pathways: Gates for Vascular Drug Delivery
Current Vascular Pharmacology